Blinatumomab
Antibody
UPDATE 1-Lonza says to make blood cancer drug for MicrometUPDATE 1-Lonza says to make blood cancer drug for Micromet * Lonza to make blinatumomab for clinical trials * Drug has shown early results for leukemia, non-Hodgkin's Swiss drugs industry supplier Lonza Group <LONN.VX> has agreed with... In this article: Lonza Group, Cancer, Blinatumomab, Leukemia, Acute lymphoblastic leukemia, Hodgkin's lymphoma, and U.S. |
-
Medical News Today | August 15, 2008
Clinical Data Published In 'Science' Show Tumor Regressions In Relapsed Lymphoma Patients Treated With T Cell Engaging BiTE Antibody Blinatumomab
Clinical Data Published In 'Science' Show Tumor Regressions In Relapsed Lymphoma Patients Treated With T Cell Engaging BiTE Antibody Blinatumomab Lymphoma / Leukemia News Clinical Data Published In 'Science' Show Tumor Regressions In...
In this article: Cancer, Antibody, Adecatumumab, Hodgkin's lymphoma, Acute lymphoblastic leukemia, Monoclonal antibodies, MedImmune, and Leukemia
-
New Data Published In Immunobiology Describe Mode Of Action Of BiTE Antibody MT110
...gastric or lung cancers. Phase 1 and 2 clinical trials are also under way for the BiTE antibody blinatumomab (MT103, MEDI-538) in patients with non-Hodgkin's lymphoma and acute B-lymphoblastic leukemia. Updates for these two clinical...
In this article: Cancer, Breast cancer, Adecatumumab, Antibody, Bayer Schering Pharma AG, Leukemia, Chronic myelogenous leukemia, and Adenocarcinoma
-
PR Newswire: Health / Biotech | December 08, 2008
Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
...Treatment for Aggressive Leukemias Interim Data from a Phase 2 Clinical Trial in B-Precursor Acute Lymphoblastic Leukemia Show that Blinatumomab is Able to Eliminate Minimal Residual Disease /PRNewswire-FirstCall/ -- Micromet, Inc.
In this article: Cancer, Antibody, Adecatumumab, Leukemias, Acute lymphoblastic leukemia, Targeted therapy, Chemotherapy regimens, Breast cancer, and American Society of Hematology
-
Prime Newswire | November 05, 2009
Micromet Buys Out MedImmune's Remaining Rights to Blinatumomab
...pivotal study that we expect to initiate in 2010." Blinatumomab is a novel therapeutic antibody that activates a patient's T cells to seek out and destroy lymphoma and leukemia cells. At the recent meeting of the European Hematological...
In this article: MedImmune, Cancer, North America, Bayer Schering Pharma, Leukemia, Monoclonal antibodies, Nycomed, and Merck Serono
-
www.ncbi.nlm.nih.gov
Immunotherapy of lymphoma and leukemia with T-cell engaging ...
Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. ... With blinatumomab (MT103) a first antibody, which can potentially ...
-
www.datamonitor.com
Datamonitor - Micromet and MedImmune initiate treatment in ...
... BiTE antibody blinatumomab in patients with adult acute lymphoblastic leukemia. ... Blinatumomab is a T cell engaging antibody targeting the CD19 antigen, which is ...
-
www.glgroup.com
Blinatumomab for Leukemia & Lymphoma; MedImmune Hands it Back ...
Blinatumomab (MT103/MEDI-538) has a complicated and unique mechanism of action. ... Home > Healthcare > GLG News > Blinatumomab for Leukemia & Lymphoma; MedImmune H...
-
www2.prnewswire.com
Micromet and MedImmune Commence Treatment in Phase 2 Trial of ...
... Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia ... Blinatumomab is a T cell engaging antibody targeting the CD19 antigen, which is ...
-
www.examiner.com
Micromet Receives European Orphan Drug Designation for ...
Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab, BETHESDA, Md., Aug. 3
Trends
Loading...
More on Blinatumomab
Description from Wikipedia:
Blinatumomab (MT-103) is a fusion protein/immunoglobulin that has anti-cancer properties. It belongs to a new class of constructed antibodies (BiTE) that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells.
The drug was developed by an German-American company Micromet, Inc. in cooperation with MedImmune.
Explore everything named Blinatumomab...
